Aqua Pharmaceuticals Welcomes Skip Williams as Executive Director of Product Development

Aqua Pharmaceuticals Welcomes Skip Williams as Executive Director of Product Development


WEST CHESTER, Pa.--(BUSINESS WIRE)--Nov 8, 2010 - West Chester-based Aqua Pharmaceuticals today announces the addition of Skip Williams as executive director of product development.

"We are excited to bring Skip on to our senior management team," said Jay Gooding, Aqua CEO. "We believe his foundational experience - gained at both Watson and other healthcare organizations - will prove invaluable to Aqua and our organizational objectives."

Williams joins Aqua following an executive director position at Watson Pharmaceuticals, where he was responsible for brand and biologics business development since 2004. In that role, he developed new products for Watson's nephrology practice, spearheaded its entry into biologics and directed the rationalization and disposition of the company's dermatology business. Prior to Watson, Skip was senior director of acquisitions at Lexis-Nexis Martindale Hubbell where he directed new product development via acquisitions.

Skip spent 15 years in the pharmaceutical industry in leadership positions at both System Software Associates, where he was global head of its pharmaceutical practice and Accenture, where he rose to senior manager in its pharmaceutical group. Williams holds a degree in organometallic chemistry from Furman University, and he also has banking experience from Citizens and Southern Bank in Atlanta, Ga. Williams is a member of the Global Licensing Executives Society.

About Aqua Pharmaceuticals

West Chester, Pennsylvania-based Aqua Pharmaceuticals is a specialty pharmaceutical company focusing on acquiring, developing and marketing prescription dermatology products. Aqua is a portfolio company of Roundtable Healthcare Partners, an operating-oriented private equity firm which has raised $1.9 billion in private equity funds and has invested more than $250 million in capital over the past year in healthcare related transactions. For more information, visit www.aquapharm.com.

 

 

Contact: Aqua Pharmaceuticals
Abbey Madden, 610-644-7000
[email protected]

 

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.